Target trials of preconception switch from nevirapine or efavirenz-based antiretroviral therapy to dolutegravir-based antiretroviral therapy on adverse birth and maternal outcomes
- 12 August 2025
- journal article
- Published by Wolters Kluwer Health in AIDS
- Vol. 39 (14) , 2103-2113
Abstract
Objective: To compare the effect of preconception switching from nevirapine (NVP) and efavirenz (EFV) to dolutegravir (DTG) based antiretroviral therapy (ART) on adverse birth and maternal outcomes. Design: Two target trial emulations using the Tsepamo Birth Outcomes Surveillance Study in Botswana. Methods: Among individuals who initiated NVP or EFV, we compared those who switched to DTG with those who did not switch prior to pregnancy. We estimated adjusted risk ratios and 95% confidence intervals (95% CIs) for any adverse birth outcome (stillbirth, neonatal death, preterm delivery, or small-for-gestational-age), any severe adverse birth outcome (stillbirth, neonatal death, very preterm delivery, or very small-for-gestational-age), low (n = 1054) with nonswitchers ( n = 3163), risk ratios (95% CIs) were 0.81 (0.74–0.89) for any adverse birth outcome, 0.81 (0.68–0.96) for any severe adverse birth outcome, 0.74 (0.57–0.96) for early pregnancy weight less than 50 kg, 1.35 (1.15–1.59) for early pregnancy weight at least 80 kg, and 0.93 (0.82–1.06) for maternal hypertension. Comparing EFV to DTG switchers (n = 1,538) with nonswitchers ( n = 7227), risk ratios (95% CIs) were 0.99 (0.91–1.07) for any adverse birth outcome, 1.05 (0.91–1.22) for any severe adverse birth outcome, 0.93 (0.78–1.12) for early pregnancy weight less than 50 kg, 1.22 (1.06–1.39) for early pregnancy weight at least 80 kg, and 1.29 (1.14–1.45) for maternal hypertension. Conclusion: Preconception switch from NVP to DTG may reduce the risk of adverse maternal and infant outcomes. Switch from EFV to DTG had no clear associations with adverse infant outcomes but may increase the risk of maternal hypertension.Keywords
This publication has 22 references indexed in Scilit:
- Protease inhibitor-based antiretroviral therapy in pregnancy: effects on hormones, placenta, and deciduaThe Lancet HIV, 2022
- Efficacy and safety of dolutegravir with emtricitabine and tenofovir alafenamide fumarate or tenofovir disoproxil fumarate, and efavirenz, emtricitabine, and tenofovir disoproxil fumarate HIV antiretroviral therapy regimens started in pregnancy (IMPAACT 2010/VESTED): a multicentre, open-label, randomised, controlled, phase 3 trialThe Lancet, 2021
- Exploring the impact of HIV infection and antiretroviral therapy on placenta morphologyPlacenta, 2021
- Weight gain during pregnancy among women initiating dolutegravir in BotswanaeClinicalMedicine, 2020
- Dolutegravir plus Two Different Prodrugs of Tenofovir to Treat HIVNew England Journal of Medicine, 2019
- Comparative safety of dolutegravir-based or efavirenz-based antiretroviral treatment started during pregnancy in Botswana: an observational studyThe Lancet Global Health, 2018
- Comparative Safety of Antiretroviral Treatment Regimens in PregnancyJAMA Pediatrics, 2017
- Benefits and Risks of Antiretroviral Therapy for Perinatal HIV PreventionNew England Journal of Medicine, 2016
- INTERGROWTH-21st very preterm size at birth reference chartsThe Lancet, 2016
- International standards for newborn weight, length, and head circumference by gestational age and sex: the Newborn Cross-Sectional Study of the INTERGROWTH-21st ProjectThe Lancet, 2014